AngioDynamics Inc. (NASDAQ:ANGO) shares fell to a low of $9.631 before closing at $9.81. Intraday shares traded counted 0.31 million, which was -13.69% lower than its 30-day average trading volume of 275.61K. ANGO’s previous close was $9.78 while the outstanding shares total 38.00M. The firm has a beta of 0.70. The stock’s Relative Strength Index (RSI) is 43.36, with weekly volatility at 4.96% and ATR at 0.63. The ANGO stock’s 52-week price range has touched low of $7.48 and a $22.09 high. The stock traded higher over the last trading session, gaining 0.31% on 06/26/20.
Investors have identified the Medical Instruments & Supplies company AngioDynamics Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $368.66 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
AngioDynamics Inc. (ANGO) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 129046000 million total, with 48712000 million as their total liabilities.
ANGO were able to record -24.19 million as free cash flow during the third quarter of the year, this saw their quarterly net cash flow reduce by -200.48 million. In cash movements, the company had a total of -18.43 million as operating cash flow.
Potential earnings growth for AngioDynamics Inc. (ANGO)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the third quarter of the year, AngioDynamics Inc. recorded a total of 69.78 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 6.1% coming in sequential stages and their sales for the third quarter reducing by -0.32%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 29.48 million trying to sell their products during the last quarter, with the result yielding a gross income of 40.3 million. This allows shareholders to hold on to 38.00M with the revenue now reading 0.00 cents per share. This is a figure that is close to analyst’s prediction for their fourth quarter (-0.03 cents a share).
Having a look at the company’s valuation, the company is expected to record 0.83 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on ANGO sounds very interesting.
Is the stock of ANGO attractive?
In related news, President and CEO, Clemmer James C bought 15,000 shares of the company’s stock in a transaction that recorded on Oct 25. The purchase was performed at an average price of 14.19, for a total value of 212,850. As the purchase deal closes, the Director, Gould Kevin J now sold 13,650 shares of the company’s stock, valued at 292,793. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.90%.
0 out of 3 analysts covering the stock have rated it a Buy, while 3 have maintained a Hold recommendation on AngioDynamics Inc.. 0 analysts has assigned a Sell rating on the ANGO stock. The 12-month mean consensus price target for the company’s shares has been set at $14.00.